National STIQ Day
National STIQ day was introduced in 2010 and every year since then the 14th of January has been dedicated to raising awareness for STIQ. The purpose is to emphasize the importance of sexual health and to encourage everyone to get regular health checks.
Sexually Transmissible Infections (STIs) are infections passed from one person to another through unprotected vaginal, oral, or anal sex, or genital contact.
Lack of symptoms
More and more people in the UK are catching STIs and each year the infection rate is rising. According to The World Health Organization (WHO), more than 1 million STIs are acquired every day and the majority of these STIs have no symptoms.1 Therefore you could have an STI and not be aware. 70% of women and 50% of men show no symptoms after contracting Chlamydia which is the most common STI condition in the UK.2
Even though the majority of the time symptoms of STIs aren’t visible, there can be signs of having an STI, including unusual discharge from the vagina, penis or anus, pain when peeing, lumps or skin growth around the genitals, a rash, unusual bleeding, itchiness or blisters around the genitals.3
What to do when you catch an STI
Anyone can catch an STI regardless of what age you are, your sexuality or how many sexual partners you have, as it only takes one sexual encounter to put you at the risk of catching an STI. A shocking fact from Public Health England shows that a case of chlamydia or gonorrhea is diagnosed in a young person every 4 minutes in England, and over 144,000 diagnoses of these sexually transmitted infections are seen in people aged 15 to 24 in 2017. 4
It is extremely important to get routinely tested. The earlier the diagnosis is made and treated the less chance of having long-term effects including infertility.
Randox Biosciences 10-plex STI test
Randox Biosciences would like to take the opportunity to support STIQ day by offering our CE marked 10-plex STI test, a cost-effective solution for accurate STI testing. This test detects the following 10 infections simultaneously from a single patient urine sample.
- Neisseria gonorrhoea (NG)
- Mycoplasma genitalium (MG)
- Ureaplasma urealyticum (UU)
- Chlamydia trachomatis (CT)
- Trichomonas vaginalis (TV)
- Haemophilus ducreyi (HD)
- Mycoplasma hominis (MH)
- Treponema pallidum (TP)
- Herpes simplex virus 1 (HSV-1)
- Herpes simplex virus 2 (HSV-2)
Does your laboratory or clinic carry out STI testing? Our molecular analyser, the Bosch Vivalytic, powered by our award winning Biochip Array Technology, could be the diagnostic solution.
For more information about our STI Arrays or Vivalytic email: email@example.com
The Evidence Evolution is a fully automated immune-analyser with random access. The machine has the capability to process up to 2640 tests per hour with up to 44 analytes screened per biochip. With a wide range test menu Randox can offer the market the service they expect with state-of-the-art intuitive touchscreen software and advanced precision bio-drive robotics.
Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.
Metabolic disease is very common. Studies state that the serious health condition affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.
Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.
1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:
- Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
- Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
- HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
- Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
- Fasting glucose of 100 mg/dL or greater
There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.
Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.
Metabolic Syndrome Array I
- Interleukin-6 (IL-6)
- Plasminogen Activator Inhibitor-1 (PAI-1)
- Tumour Necrosis Factor α (TNFα)
Metabolic Syndrome Array II
- C-reactive Protein (CRP)
- Cystatin C
For more information on our Evidence Series or Metabolic Syndrome Range of Assays, contact us at EvidenceSeries@randox.com
Familial Hypercholesterolemia (FH) is a genetic disorder where the child is born with extremely high cholesterol levels. FH can trace back through several generations. Cholesterol is vital for the normal function of the human body therefore, it is important to ensure the cholesterol levels don’t get too high because it can result in early onset cardiovascular disease. 1
The FH Foundation states an interesting fact that 1 in 250 people worldwide have FH and over 90% of these people have not been properly diagnosed 2. Majority of these people won’t know they have FH disease until they have a heart attack!
However, there are no clear symptoms if someone has FH until it is too late and the damage has been done. The warning signs include the following:1
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Gray-white cholesterol deposits around the corneas
A study in 2008 by the British Heart Foundation found that people with FH who are diagnosed and treated before they develop heart disease live as long people who don’t have FH 4. This theory emphasis the importance of getting early diagnosis to prevent long-term problems. Treatment to prevent cardiovascular disease involves taking medication prescribed by the doctor and making lifestyle changes including; modifying diet, increasing exercise, quit smoking, decrease drinking alcohol and ensure the patient gets regular sleep.
Randox offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time allowing results to be reported within days compared to NHS waiting lists which can be substantially longer. The two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes. The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing with NGS. The genetic analysis for FH mutations allows for more accurate diagnosis compared to lipid profiling.
Randox can help using the award-winning Biochip Analyser to achieve early and appropriate treatment for those with FH resulting those to adopt a healthier lifestyle and taking cholesterol-lowering medication, risk of heart disease to live a longer and healthy life!
Familial Hypercholesterolemia (FH) Arrays I & II:
- LDLR – 38 mutations
- APOB – 1 mutation
- PCSK9 – 1 mutation
To find out more about the products that we offer email us firstname.lastname@example.org
The Evidence is the world’s first protein Biochip Array Technology Analyser (BAT). The awarding winning Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
The Evidence is a fully automated immunoanalyser which is renowned for higher standards of quality, efficiency and reliability. It is tailored and more suitable in a wide range of settings including hospital laboratories, clinical laboratories, private and public research applications, veterinary laboratories, forensic and clinical toxicology and pharmaceutical applications.
There are many key features for The Evidence, including the ability to carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample as a result. It reduces the amount of labour spent on the individual tests and therefore saves money and time. The analyser is more suitable for larger laboratories with a throughput of >1500 tests per hour with a fully automated system maximising the walk away time – allowing staff to devote their time to other important tasks.
The multi-analyte barcoded controls and calibrators ensure security, accuracy and reliable laboratory testing. They also allow for full traceability making the overall experience easier. It offers a wide-ranging and diverse test menu which offer more tests than other sole suppliers and this will benefit many research areas including immunology, metabolic, cardiovascular and oncology.
Neurological conditions can affect young and old people and result from damage to the brain, spine or nerves which is triggered by an illness or an injury1. Up to 1 billion people (one in six of the world’s population suffer from neurological disorders from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy 2. In England the number of deaths from neurological disorders have rose by 39% over the past 13 years3.
Randox offers two Cerebral Arrays which have been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The Arrays can measure up to five biomarkers simultaneously. They are suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Additionally, it offers excellent sensitivity, precision and recovery as well as analytical performance.
For more information on our Evidence Series or Cerebral range of Assays, contact us at EvidenceSeries@randox.com
Mental Health Day is held every year on the 10th of October since 1992 1 to raise awareness and support against the stigma. 1 in 4 people in the UK will experience mental illness each year 2.
“Everyone has mental health. It involves our emotional, psychological and social well-being and it affects how we feel, think and act” 3 Mental Health can also affect an individual’s daily life, relationships and physical health. Lives are taken as a result from mental health therefore it is vital that we acknowledge the syndromes of mental health in order provide help and support.
Randox held a mental health and well-being month. This entailed a yellow shirt day, an organised free-fall abseiling from the dome of Victoria Square, cake sale and yoga throughout the month! Randox care for the health of their staff and want to ensure that mental health is just as important as physical and that it is ok to not be ok.
At Randox Biosciences, we are devoted to the development of innovative diagnostic tests to improve patient care worldwide. We strive to maintain a stress-free environment for our employees by recognising the signs of mental health to lower mental health in order to create a positive working environment.
- Reach out. If you feel like you experience mental health, talk to someone. It will lift the weight off your shoulders and you could get the help you require.
- Do something you enjoy! It can be a hobby or spending time with your family and friends.
- Go for a walk. Fresh air can clear a head.
- Take time out of digital devices. Technology have taken over and sometimes taking an hour off social medias can help.
- Sleep more. Having a full night’s sleep can change your mood completely.
- Eat well and exercise. It is easy to forget your physical health. When you have a nutritional diet and exercise regularly, you’re stronger and healthier.
- Avoid alcohol and drug-use.
Help-lines for mental health include the following:
To find out more email us at email@example.com
Biochip Array Technology
In 1992, Randox invested £180 million to create and introduce Biochip Array Technology (BAT) which converted laboratory testing. Randox came up with the innovation by recognising the major problem with traditional diagnosis. Within traditional diagnosis several tests are typically required which involves multiple blood draws from the patient, many visits to the hospital, increased reagent volume and increased time to diagnosis. Biochip Array Technology allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from one single sample. Therefore, it is faster, cost saving and more effective leading to better clinical decisions. Today the technology (BAT) is used in countless laboratories worldwide and a range of three biochip analysers are now offered.
The main basis of the Biochip Array Technology
- 9x9mm biochip which acts as a solid phase reaction vessel.
- Each of the biochips are pre-coated with an array of discrete test regions (DTRs)
- One biochip per sample used to generate multiple results.
- Randox Biochips hold up to 49 tests.
- Based on chemiluminescent signal emitting light, without heat which results a chemical reaction.
The key features and benefits of the Biochip Array Technology
Highly accurate testing
- The biochip array technology provides high standard of accurate test results with CV’s <10%
- Multiplex analysis minimises analytical variation between the tests.
- Increased patient information available through testing multiple markers
- Patients receive their results quicker compared to the traditional diagnosis.
Reduced sample volume
- Reduced sample required therefore patients feel more at ease.
Wide test menu
- Wide test menu provides a variety for clients and allows flexibility.
- Multiple samples can be used on BAT which include the following; serum, plasma, whole blood, urine and many others which allows for flexibility in their testing
– The process reduces the amount of time spent on individual tests and associated laboratory costs
Biochip testing platforms
The Evidence Evolution is fully automated random-access biochip testing platform. The machine allows any test to perform at any time as it is a highly versatile analyser which can operate any workflow. It can receive 2640 tests per hour which means the machine has a fast turnaround time. As well as this, it allows multiple tests to be performed from a single sample which reduces time and resources spent on individual tests. The Evidence Evolution can be tailored to certain laboratory needs and have features including automatic start-up and shut down, relaxed testing capability and traceability of biochips. The equipment overall is made to be easy for the client to use as it includes customisable user settings and easy to follow result screens giving them the fast and accurate operations they would prefer.
The Evidence Analyser is the protein Biochip Array technology. Like the Evidence Evolution it is fully automated which is suitable for busy laboratories, hospitals, forensic and clinical toxicology. The machine is floor standing and can receive up to 3690 per hour. The machine has features such as easy to follow software and customisable user settings which gives laboratories the opportunity to receive fast and accurate results.
The Evidence Investigator is often used for research, clinical, forensic, molecular and veterinary testing. The machine is semi-automated and can combine immunoassay and molecular diagnostics on a single platform with protein and DNA biochips. This machine also has a quick turnaround time with the ability to achieve 2376 tests per hour with 44 analytes screened per biochip. The evidence investigator provides more tests on the test menu which allows variety.
The final platform is the Evidence MultiSTAT. The Evidence MultiSTAT is a fully-automated analyser which provides quality results. It is a simple and easy to use analyser which requires minimal training with only three steps to complete the process. The machine can provide multiplex testing yields up to 46 results in under ten minutes. It is ease-of-use for non-laboratory staff and provides full traceability of user action with password controlled software.
Evidence Investigator | Adaptable, Efficient & Comprehensive
The Evidence Investigator is a compact, semi-automated benchtop analyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, research, toxicology and food diagnostics.
Renowned for its versatility, robustness and effective reporting methods, the Evidence Investigator has been used in a wide range of laboratory settings for over 15 years. This highly advanced yet simple to use analyser has only one moving part, giving the user peace of mind.
The Evidence Investigator contains a host of innovative on-board data analysis features ensuring manual processes are kept to a minimum.
By utilising the same multiplex technology as the other Evidence Series analysers, the Evidence Investigator can process up to 44 results from a single sample, with a maximum throughput of up to 2376 tests per hour. Offering efficiency without compromising on accuracy, the Evidence Investigator is the perfect fit for medium throughput laboratories seeking maximum use of bench space.
Our molecular product range offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infection (STI), Respiratory tract infection, colorectal cancer, familial hypercholesterolemia (FH) and cardiovascular disease (CVD). Additionally, we can provide a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection.
STI and Respiratory Arrays
Both arrays detect the most common and frequently requested infections in sexual and respiratory health. These comprehensive, highly sensitive and specific tests enable identification of co-infections simultaneously, often in asymptomatic patients and enable antibiotic stewardship.
KRAS, BRAF, PIK3CA array and Familial Hypercholesterolemia Arrays I & II
These unique biochip assays permit high discrimination between multiple targets in a number of genes with a rapid turnaround time (3 hours). The arrays enable detection of the most frequently occurring mutations known to cause disease (FH) and adversely affect patient treatment (KRAS, BRAF, PIK3CA). A unique primer set is designed for each target which will hybridise to a complimentary oligo-nucleotide probe spotted on a biochip discrete test region (DTR).
Cardiovascular Risk Prediction Array
This array identifies individuals with a genetic predisposition to coronary heart disease (CHD). The innovative multiplex primers are designed to discriminate DNA sequences which differ only at one base.
For more information on our Evidence Series or Molecular range of Assays, contact us at EvidenceSeries@randox.com
World Alzheimer’s Month
World Alzheimer’s Month is a global campaign to raise awareness and highlight the challenge that surrounds the disease, hosted by the Alzheimer’s disease International (ADI) every September. During this month World Alzheimer’s Day also takes place, 21 September each year.
47 million people are living with Alzheimer’s worldwide, costing 604 billion USD per year. This number is expected to rise to 76 million people with the disease by 2030.1 The FDA have not approved a medication for the treatment of Alzheimer’s disease since 2003. More than 400 clinical trials are currently looking at new treatments for Alzheimer’s disease (AD) and many of them are actively recruiting. Many still regard the amyloid hypothesis as a key explanation for Alzheimers disease development and progression.2
Alzheimer’s disease is not necessarily inherited as a single-gene mutation as the inheritance pattern is incredibly complex. Unlike familial Alzheimer’s disease, a multi-gene form usually affects those aged 65 and older. The gene with the greatest known effect on the risk of developing late-onset Alzheimer’s disease is called apolipoprotein E (APOE). It is found on chromosome 19 and the APOE protein plays a role in handling fats in the body, including cholesterol. 3
ApoE plays a key role in lipid metabolism and the scientific and medical community recognise it as one of the most powerful genetic risk factors for dementia and other neurodegenerative diseases. It has become one of the most widely studied gene variants in Alzheimer’s disease and constitutes a major consideration for preventive medicine.
ApoE exists in three common isoforms (ApoE2, ApoE3 and ApoE4) which are coded by three co-dominant alleles (e2, e3, e4). As such, six common ApoE phenotypes exist within the general population: E2/E2, E3/E3, E4/E4 (homozygous) and E2/E3, E2/E4, E3/E4 (heterozygous). Medical professionals recognise the presence of the ApoE4 isoform as a major genetic risk factor for development of Alzheimer’s disease. Therefore, the availability of analytical methods for rapid and reliable ApoE4 classification is advantageous.
The Apolipoprotein E4 (ApoE4) Array is a research use only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.
2-plex Biochip Array
- Pan ApoE
An individual’s ApoE status has been shown to affect pre-symptomatic risk, diagnosis, prognosis, and treatment response for a variety of diseases, in particular Alzheimer’s disease. The ApoE4 Array can rapidly and accurately detect an individual’s ApoE4 status directly from a plasma sample. In combination with medical and family history, medication and lifestyle, this can deliver valuable information for personalised medicine approaches.
The 2-plex diagnostic Alzheimer’s test has the utility to detect the likelihood of a person’s chance of developing the disease to assist in the research and development of a potential drug to combat or slow down the process of Alzheimer’s.
For further information about the Randox Alzheimer’s Array, please email firstname.lastname@example.org
Randox Biosciences is a world-leading primary manufacturer of high quality monoclonal and polyclonal antibodies, antibody fragments and human recombinant proteins. Our team of scientists possess unrivalled expertise which enables us to provide you with a comprehensive suite of products and services dedicated to advancing biopharmaceutical research and diagnostics.
Randox Biosciences offers an extensive portfolio of over 900 products for a multitude of R&D applications including more than 500 monoclonal and polyclonal antibodies and over 140 human recombinant proteins as well as antibody fragments, buffers & diluents and plasma.
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; cardiovascular/cerebrovascular and metabolic/Nutrition
- Drugs of abuse: Alcohol, anti-depressants, barbituates, hallucinogens, opiates, stimulants
- Drug Residues: antimicrobial drugs, growth promoters, mycotoxins
- Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; Immunology, Oncology, Cardiovascular/Cerebrovascular and Metabolic/Nutrition
- Drugs of abuse: Alcohol, Analgesics, Anti‑depressants, Barbituates, Benzodiazepines, Hallucinogens, Opiates, Sedatives, Stimulants, Synthetic Drugs, Therapeutic drugs
- Drug Residues: Anti-inflammatory Drugs, Antimicrobial Drugs, Anti-Parasitic Drugs, Growth Promoters, Mycotoxins
Recombinant Antibody Fragments
- Single chain variable fragment (scFvs)
- Single domain antibodies (sdAbs)
Frozen Human Plasma
- Available in three formats (Male, Female and Mixed Gender)
- Highly screened for; HIV, Hepatitis B+C, HTLV I + II, Syphilis, CMV and Procleix WNV
Human Recombinant Proteins (E.Coli & Mammalian)
- Adhesion Molecules
- Tumour markers
Buffers & Diluents
- Complementary range available
Key Features & Benefits
- All products manufactured at our ISO 13485 accredited UK manufacturing plant
- Product range of over 900 products
- 30 years’ experience in raw material manufacture and assay development
- Many unique and novel products including designer drugs, Mycotoxins and oncology markers
- As our host animals are sheep, our antibodies have higher sensitivity and specificity
- Excellent reproducibility between lot numbers
- Products reflect the components used in-house in the production of Randox diagnostic products and research programs
- Highly experienced in developing difficult targets (i.e. small molecules and novel biomarkers)
- Full customisation service available
- A range of pack sizes available including bulk quantities for commercial development
- Products can be used in a multitude
Custom Development Services
To meet your precise requirements, Randox Biosciences offer customised antibody generation services to the pharmaceutical and biotechnology industry. Our custom development service, which encompasses antibodies and human recombinant proteins has achieved tremendous success within the biopharmaceutical and diagnostic industries. Key components of our custom service are our range of monoclonal antibodies as well as our recombinant antibody fragments (sdAbs, scFvs, fAbs).
Our customisation service has proven incredibly successful in the research and development industries allowing access our expertise to obtain the antibody and protein most relevant to your line of work. With over 300 highly trained research scientists and over 30 years’ experience in commercial assay development, Randox Biosciences can also provide a tailor-made assay development service to meet your specifications in both a timely and cost-effective manner.
For more information contact: info@Randoxbiosciences.com
Leading diagnostics firm Randox Laboratories has this week sent a delegation of scientists from its Biosciences Division to take part in the UK Exhibition of Oncology Excellence, between 25th and 29th June in Beijing and Guangzhou, in China.
The centrepiece of the UK-China Oncology Congress, the exhibition has been carefully curated to follow the “Science to Patient Pathway” for new therapies – from research to clinical trials, regulatory approval, manufacturing and distribution.
The Randox Biosciences team, over the course of the Congress event, will join a range of cancer-related seminars, offering an opportunity to learn about and influence Chinese government policies and priorities, and explore the latest trends and hot topics in oncology.
Julie-Ann O’Hare, Sales and Marketing Director for Randox Biosciences, commented;
“At Randox Biosciences we are actively seeking opportunities to strengthen business ties between the UK and China, and of course to showcase our innovative diagnostic capabilities to what is one of our most important and growing markets.
“We continue to expand our business presence there thanks to the ongoing pipeline of novel tests being produced from our innovative research and development programmes and enhanced manufacturing capabilities, including new facilities at the Randox Science Park in Northern Ireland.”
Exhibiting to a diverse audience of universities, hospitals, and laboratories responsible for prevention, diagnosis, treatment and care in oncology, Randox Biosciences have joined the exhibition to showcase their innovative diagnostic tests for bladder cancer and early detection of renal toxicity – including Chronic Kidney Disease and Acute Kidney Injury.
“We continue to offer an increasing range of innovative diagnostic biomarkers to the growing and dynamic biotechnology markets.
“The focus on the importance of scientific research in the patient pathway, in enabling cancer diagnoses as soon as possible, offers us the perfect platform to introduce to China our latest pioneering oncological tests, including our test for bladder cancer.
“This test can stratify patients with haemeaturia (blood in the urine), who are at high risk of bladder cancer – reducing the number of unnecessary cystoscopies carried out on patients identified as ‘low risk’, significantly reducing healthcare costs and improving the waiting times for haematuria patients.”
For further information about the UK-China Oncology Congress, please email email@example.com